[VIEW] agent=Quality & Patient Safety Director | scenario_id=107 | rounds=20

--- Round 0 ---
[R0.1] Quality & Patient Safety Director (speak, public): Good morning, everyone. As we discuss the 60-day corrective action plan to improve inpatient medication reconciliation reliability, I'd like to start by highlighting our current state. Our baseline compliance audit shows that admission med rec is completed within 24 hours at 71%, and discharge reconciliation is completed before discharge at 62%. The defect theme breakdown indicates unclear ownership and after-hours admissions as top contributors.
[R0.2] Pharmacy Informatics Lead (speak, public): From an informatics perspective, our current medication reconciliation workflow involves 6 steps with pharmacist verification taking an average of 18 minutes per patient. The proposed EHR change includes a discharge hard-stop for 'Reconcile and Sign', which is expected to improve compliance. We estimate 120 hours of build effort and a 2-week testing cycle. Additionally, we've planned a microlearning module for training, which is 15 minutes long and targets 850 learners.
[R0.3] Hospital Finance & Operations Director (speak, public): Thank you both for the detailed overview. To better understand the financial and operational implications, can you help me quantify the potential impact of improving medication reconciliation on reducing preventable Adverse Drug Events (ADEs)?

--- Round 1 ---
[R1.1] Quality & Patient Safety Director (speak, public): While we don't have a direct quantification of the impact on reducing preventable Adverse Drug Events (ADEs), our defect theme breakdown suggests that addressing unclear ownership and after-hours admissions could significantly improve our medication reconciliation process. I'd like to highlight that our current compliance rates are 71% for admission med rec within 24 hours and 62% for discharge reconciliation before discharge. Improving these rates should contribute to a safer patient environment.
[R1.2] Pharmacy Informatics Lead (speak, public): To better understand the operational implications, I'd like to clarify that our proposed EHR change is designed to enforce a more structured medication reconciliation process. The discharge hard-stop for 'Reconcile and Sign' should help improve our discharge reconciliation rate. However, we need to consider the 120 hours of build effort and the subsequent 2-week testing cycle. Additionally, training 850 learners through a 15-minute microlearning module is expected to be manageable.
[R1.3] Hospital Finance & Operations Director (speak, public): To better assess the financial viability of the proposed 60-day corrective action plan, can you provide more details on the estimated costs associated with the EHR build effort and the training module for the 850 learners?

--- Round 2 ---
[R2.1] Quality & Patient Safety Director (speak, public): To address the financial and operational implications, I'd like to summarize that our primary goal is to improve medication reconciliation reliability within 60 days. We've identified that unclear ownership and after-hours admissions are significant contributors to our current compliance issues. The proposed EHR changes and training should help address these gaps. I'd like to request that we discuss the budget allocation for the 120 hours of EHR build effort and the training module for 850 learners. Additionally, understanding the potential impact on our day-to-day operations and how we can mitigate any disruptions is crucial.
[R2.2] Pharmacy Informatics Lead (speak, public): To address the financial implications, I can confirm that the 120 hours of EHR build effort will require dedicated informatics resources. The estimated cost for this effort should be aligned with our current IT project budgeting. For the training module, the 15-minute microlearning approach is designed to be efficient and minimize disruption to our clinical staff's workflow. We should be able to absorb the training costs within our existing education budget. However, I'd like to highlight that our proposed solution is designed to be feasible within our current workflow and technology infrastructure.
[R2.3] Hospital Finance & Operations Director (speak, public): To assess the financial viability of the proposed 60-day corrective action plan, I'd like to highlight that our estimated cost per preventable ADE is $3,200, and we had 118 preventable ADEs last year. Improving medication reconciliation reliability should help reduce this number. Can you help me understand how the proposed changes might impact our preventable ADE rate and what the associated cost savings could be?

--- Round 3 ---
[R3.1] Quality & Patient Safety Director (speak, public): To address the financial viability and potential cost savings, while we don't have exact figures on the reduction of preventable Adverse Drug Events (ADEs), improving medication reconciliation reliability is expected to contribute to a decrease in medication-related harm events. Our current compliance rates are suboptimal, and the proposed EHR changes along with the training module are designed to address the identified gaps. I'd like to suggest that we model the potential cost savings based on the estimated reduction in preventable ADEs and compare it against the costs associated with the EHR build effort and training. This will help us make a more informed decision about the 60-day corrective action plan.
[R3.2] Pharmacy Informatics Lead (speak, public): To further assess the potential impact on preventable Adverse Drug Events (ADEs) and associated cost savings, I can share that our proposed EHR changes are designed to enforce a more structured medication reconciliation process. While we don't have exact figures on the reduction of preventable ADEs, improving our compliance rates should contribute to a decrease in medication-related harm events. I'd like to suggest that we model the potential cost savings based on the estimated reduction in preventable ADEs and compare it against the costs associated with the EHR build effort and training.
[R3.3] Hospital Finance & Operations Director (speak, public): To further assess the financial viability of the proposed 60-day corrective action plan, I'd like to summarize that our estimated one-time cost is $410,000, with $240,000 attributed to staffing backfill. We need to weigh this against the potential cost savings from reducing preventable Adverse Drug Events (ADEs). Given our current operating margin constraint, we must ensure that our investment aligns with our financial goals. I suggest we model the potential return on investment (ROI) based on the expected reduction in preventable ADEs and compare it against the costs. Let's discuss the feasibility of achieving the proposed changes within the 60-day timeline and the associated costs.

--- Round 4 ---
[R4.1] Quality & Patient Safety Director (speak, public): To further assess the feasibility of the proposed 60-day corrective action plan, I'd like to summarize that our primary goal is to improve medication reconciliation reliability. We've discussed the EHR changes, training module, and associated costs. To ensure we meet the Joint Commission's Evidence of Standards Compliance due in 45 days, we need to confirm whether the proposed changes can be implemented within the given timeline. I'd like to request that we finalize our discussion on the practical scope of system changes, training effort, and resource footprint to make a decision on approving and funding the plan.
[R4.2] Pharmacy Informatics Lead (speak, public): To finalize our discussion on the 60-day corrective action plan, I'd like to confirm that our proposed EHR changes, including the discharge hard-stop for 'Reconcile and Sign', along with the microlearning training module, are designed to be feasible within our current workflow and technology infrastructure. We should be able to implement these changes within the given timeline. I recommend we move forward with approving and funding the plan, ensuring that we allocate the necessary resources for the EHR build effort and training module.
[R4.3] Hospital Finance & Operations Director (speak, public): To finalize our decision on the 60-day corrective action plan, I'd like to summarize the key points discussed. We've estimated a one-time cost of $410,000, with $240,000 for staffing backfill. The proposed EHR changes and training module are expected to improve medication reconciliation reliability, potentially reducing preventable Adverse Drug Events (ADEs). Given our current compliance rates and the potential cost savings, I recommend we approve and fund the plan, ensuring we allocate necessary resources for the EHR build effort and training. Let's confirm our ability to implement the changes within the 60-day timeline and monitor the impact on our financial and operational performance.

--- Round 5 ---
[R5.1] Quality & Patient Safety Director (speak, public): To finalize our decision on the 60-day corrective action plan, I'd like to summarize that we've discussed the EHR changes, training module, and associated costs. The proposed plan is designed to improve medication reconciliation reliability, addressing unclear ownership and after-hours admissions. Given our current compliance rates and the potential to reduce preventable Adverse Drug Events (ADEs), I recommend we approve and fund the plan. Let's confirm our ability to implement the changes within the 60-day timeline and monitor the impact on our financial and operational performance.
[R5.2] Pharmacy Informatics Lead (speak, public): To finalize our decision on the 60-day corrective action plan, I recommend we approve and fund the plan, ensuring that we allocate the necessary resources for the EHR build effort and training module. Our proposed changes are designed to be feasible within our current workflow and technology infrastructure, and we should be able to implement them within the given timeline.
[R5.3] Hospital Finance & Operations Director (speak, public): I recommend we approve and fund the 60-day corrective action plan to improve inpatient medication reconciliation reliability. The estimated one-time cost is $410,000, with $240,000 for staffing backfill. Given the potential to reduce preventable Adverse Drug Events (ADEs) and associated cost savings, I believe this investment aligns with our financial and operational goals. Let's move forward with allocating the necessary resources for the EHR build effort and training module.

--- Round 6 ---
[R6.1] Quality & Patient Safety Director (speak, public): I concur with the recommendation to approve and fund the 60-day corrective action plan. Given the discussions on the EHR changes, training module, and associated costs, I believe this plan will improve medication reconciliation reliability and reduce preventable Adverse Drug Events (ADEs). Let's proceed with allocating the necessary resources and monitoring the implementation closely to ensure we meet the Joint Commission's Evidence of Standards Compliance deadline.
[R6.2] Pharmacy Informatics Lead (leave, public): 
[R6.3] Hospital Finance & Operations Director (leave, public): 

--- Round 7 ---
[R7.1] Quality & Patient Safety Director (leave, public): 
[R7.2] Pharmacy Informatics Lead (leave, public): 
[R7.3] Hospital Finance & Operations Director (leave, public): 

--- Round 8 ---
[R8.1] Quality & Patient Safety Director (leave, public): 
[R8.2] Pharmacy Informatics Lead (leave, public): 
[R8.3] Hospital Finance & Operations Director (leave, public): 

--- Round 9 ---
[R9.1] Quality & Patient Safety Director (leave, public): 
[R9.2] Pharmacy Informatics Lead (leave, public): 
[R9.3] Hospital Finance & Operations Director (leave, public): 

--- Round 10 ---
[R10.1] Quality & Patient Safety Director (leave, public): 
[R10.2] Pharmacy Informatics Lead (leave, public): 
[R10.3] Hospital Finance & Operations Director (leave, public): 

--- Round 11 ---
[R11.1] Quality & Patient Safety Director (leave, public): 
[R11.2] Pharmacy Informatics Lead (leave, public): 
[R11.3] Hospital Finance & Operations Director (leave, public): 

--- Round 12 ---
[R12.1] Quality & Patient Safety Director (leave, public): 
[R12.2] Pharmacy Informatics Lead (leave, public): 
[R12.3] Hospital Finance & Operations Director (leave, public): 

--- Round 13 ---
[R13.1] Quality & Patient Safety Director (leave, public): 
[R13.2] Pharmacy Informatics Lead (leave, public): 
[R13.3] Hospital Finance & Operations Director (leave, public): 

--- Round 14 ---
[R14.1] Quality & Patient Safety Director (leave, public): 
[R14.2] Pharmacy Informatics Lead (leave, public): 
[R14.3] Hospital Finance & Operations Director (leave, public): 

--- Round 15 ---
[R15.1] Quality & Patient Safety Director (leave, public): 
[R15.2] Pharmacy Informatics Lead (leave, public): 
[R15.3] Hospital Finance & Operations Director (leave, public): 

--- Round 16 ---
[R16.1] Quality & Patient Safety Director (leave, public): 
[R16.2] Pharmacy Informatics Lead (leave, public): 
[R16.3] Hospital Finance & Operations Director (leave, public): 

--- Round 17 ---
[R17.1] Quality & Patient Safety Director (leave, public): 
[R17.2] Pharmacy Informatics Lead (leave, public): 
[R17.3] Hospital Finance & Operations Director (leave, public): 

--- Round 18 ---
[R18.1] Quality & Patient Safety Director (leave, public): 
[R18.2] Pharmacy Informatics Lead (leave, public): 
[R18.3] Hospital Finance & Operations Director (leave, public): 

--- Round 19 ---
[R19.1] Quality & Patient Safety Director (leave, public): 
[R19.2] Pharmacy Informatics Lead (leave, public): 
[R19.3] Hospital Finance & Operations Director (leave, public): 

